Jazz Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Jazz Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count).
Jazz Pharmaceuticals: 128 sponsored US clinical trials, 15 recruiting.
Jazz Pharmaceuticals sponsors 128 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 81 completed. 50 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Narcolepsy, with 5 trials.
Top-decile sponsor footprint
Jazz Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#212 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
81 of 108 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
128 total, page 2 of 3
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
NCT03848832
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
NCT03533114
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
NCT03555955
A Post-Marketing Observational Study of VYXEOS™
NCT03526926
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
NCT03485729
CX-8998 for Absence Seizures
NCT03406702
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
NCT03339297
ONC201 in Pediatric H3 K27M Gliomas
NCT03416530
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
NCT03339401
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
NCT03295396
A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03101241
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
NCT02954887
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
NCT02953548
Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02863991
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
NCT03030599
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
NCT03037203
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
NCT02892123
Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
NCT02851407
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
NCT02544750
Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
NCT02873338
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
NCT02544763
Oral ONC201 in Adult Recurrent Glioblastoma
NCT02525692
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
NCT02439970
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
NCT02439957
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
NCT02769780
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
NCT02224560
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
NCT02348606
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
NCT02348593
"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
NCT02348619
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
NCT02348632
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
NCT02224690
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
NCT02224703
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
NCT02091375
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
NCT02420080
An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.
NCT02325011
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
NCT02091206
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
NCT02221869
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
NCT02257684
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
NCT02238925
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
NCT02087306
The Chimerix CMX001 Registry
NCT02167685
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
NCT01843634
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
NCT01769170
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
NCT01887301
Patient Registry of Intrathecal Ziconotide Management(PRIZM)
NCT01888120
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
NCT01696084
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
NCT01643408
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
NCT01681121
A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
NCT01485770
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
NCT01461915
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 43 |
| Phase 3 | 44 |
| Phase 4 | 6 |
Therapeutic Areas
What is open in the Jazz Pharmaceuticals pipeline
15 recruiting of 128 indexed (12% open); 81 completed (63%).
Phase mix: 50 late (III/IV) vs 69 early (I/II) (balanced across stages).
Top condition: Narcolepsy (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jazz Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 128 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Jazz Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 128 trials (± recruiting share)
- University of Illinois at Urbana-Champaign · 129 trials · 14% recruiting
- Stony Brook University · 127 trials · 19% recruiting
- Rhode Island Hospital · 130 trials · 20% recruiting
- The Methodist Hospital Research Institute · 126 trials · 39% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Jazz Pharmaceuticals page
128 registered trials is a research-attention snapshot, not an endorsement of Jazz Pharmaceuticals or any single study.
- 15 of Jazz Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Narcolepsy is the condition Jazz Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Narcolepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Jazz Pharmaceuticals pipeline card: 128 registered trials from official public datasets.Report a data error.